title: [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
abstract: BACKGROUND
  Nonalcoholic Fatty Liver Disease (NAFLD) is one of the most common liver disease. Its prevalence is 20-30% in the population of developed countries, its prevalence is 26% in Russia. NAFLD is observed in many patients with Metabolic Syndrome. Because of the wide prevalence of this disease it is required to find best drugs influencing mechanisms of its development, chronicity and progression.
  
  
  METHODS
  36 patients were included to the study. Mean age of patients was 43 +/- 3.9 years. Patients of the main group received the ursodeoxycholic acid within 2 months. Patients of the control group received the plant origin hepatoprotective medicine. All patients before and after treatment were carried out the biochemical analysis of blood, the liver ultrasound examination, the bioimpedance body composition analysis, the microbiological examination of faeces, the examination of metabolites of microorganisms in the blood by the method of gas-liquid chromatography - mass spectrometry, developed by Osipov G. A.
  
  
  RESULTS
  The reduction of hepatic transaminases, the trend to normalization of the lipid profile, the reduction of body weight, the reduction of amount of adipose tissue in the body, the increase of Bifidobacterium spp., Lactobacillus spp., Enterococcus spp., the increase of levels of Bifidobacterium spp., Lactobacillus spp. Metabolites, the decrease of endotoxin plasma level and the decrease of total microbial load were observed after the UDCA treatment. The results of the study showed the prospectivity of the using of UDCA for NAFLD associated with Metabolic Syndrome.
authors.forename: E B
authors.initials: EB
authors.lastname: Avalueva
authors.forename: E I
authors.initials: EI
authors.lastname: Tkachenko
authors.forename: E V
authors.initials: EV
authors.lastname: Skazyvaeva
authors.forename: S V
authors.initials: SV
authors.lastname: Ivanov
authors.forename: E A
authors.initials: EA
authors.lastname: Orishak
authors.forename: I V
authors.initials: IV
authors.lastname: Lapinskiĭ
mesh_terms: D000328:Adult; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D012426:Russia; D013997:Time Factors; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*
chemical_list: D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid